Hypolipidemic Effects and Safety of Lactobacillus Reuteri 263 in a Hamster Model of Hyperlipidemia
by
Wen-Ching Huang 1,†, Yi-Ming Chen 2,†, Nai-Wen Kan 1,3, Chun-Sheng Ho 4,5, Li Wei 6, Ching-Hung Chan 7, Hui-Yu Huang 7,* and Chi-Chang Huang 2,4,*
Wen-Ching Huang 1,†, Yi-Ming Chen 2,†, Nai-Wen Kan 1,3, Chun-Sheng Ho 4,5, Li Wei 6, Ching-Hung Chan 7, Hui-Yu Huang 7,* and Chi-Chang Huang 2,4,*
1
Graduate Institute of Athletics and Coaching Science, National Taiwan Sport University, Taoyuan 33301, Taiwan
2
Graduate Institute of Sports Science, National Taiwan Sport University, Taoyuan 33301, Taiwan
3
Center for Liberal Arts, Taipei Medical University, Taipei 11031, Taiwan
4
College of Exercise and Health Sciences, National Taiwan Sport University, Taoyuan 33301, Taiwan
5
Division of Physical Medicine and Rehabilitation, Lo-Hsu foundation, Inc., Lotung Poh-Ai Hospital, Yilan 26546, Taiwan
6
Department of Neurosurgery, Taipei Medical University-WanFang Hospital, Taipei 11696, Taiwan
7
Department of Food Science, Nutrition, and Nutraceutical Biotechnology, Shih Chien University, Taipei 10462, Taiwan
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Nutrients 2015, 7(5), 3767-3782; https://doi.org/10.3390/nu7053767
Received: 11 March 2015 / Revised: 8 April 2015 / Accepted: 12 May 2015 / Published: 15 May 2015
(This article belongs to the Special Issue Microbiome and Human Health)
We aimed to verify the beneficial effects of probiotic strain Lactobacillus reuteri 263 (Lr263) on hypolipidemic action in hamsters with hyperlipidemia induced by a 0.2% cholesterol and 10% lard diet (i.e., high-cholesterol diet (HCD)). Male Golden Syrian hamsters were randomly divided into two groups: normal (n = 8), standard diet (control), and experimental (n = 32), a HCD. After a two-week induction followed by a six-week supplementation with Lr263, the 32 hyperlipidemic hamsters were divided into four groups (n = 8 per group) to receive vehicle or Lr263 by oral gavage at 2.1, 4.2, or 10.5 × 109 cells/kg/day for 6 weeks, designated the HCD, 1X, 2X and 5X groups, respectively. The efficacy and safety of Lr263 supplementation were evaluated by lipid profiles of serum, liver and feces and by clinical biochemistry and histopathology. HCD significantly increased serum levels of total cholesterol (TC), triacylglycerol (TG) cholesterol, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), LDL-C/HDL-C ratio, hepatic and fetal TC and TG levels, and degree of fatty liver as compared with controls. Lr263 supplementation dose dependently increased serum HDL-C level and decreased serum TC, TG, LDL-C levels, LDL-C/HDL-C ratio, hepatic TC and TG levels, and fecal TG level. In addition, Lr263 supplementation had few subchronic toxic effects. Lr263 could be a potential agent with a hypolipidemic pharmacological effect.
View Full-Text
Keywords:
hypolipidemic; cholesterol; triglyceride; high-cholesterol diet; lipid-lowering
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Huang, W.-C.; Chen, Y.-M.; Kan, N.-W.; Ho, C.-S.; Wei, L.; Chan, C.-H.; Huang, H.-Y.; Huang, C.-C. Hypolipidemic Effects and Safety of Lactobacillus Reuteri 263 in a Hamster Model of Hyperlipidemia. Nutrients 2015, 7, 3767-3782.
Show more citation formats
